Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Cha University Industry-Academic Cooperation Foundation is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. The data shows that 3 distinct examiners are involved in reviewing these cases, indicating a broad distribution of the company's intellectual property across different personnel. Furthermore, the workload is spread across 3 distinct art units, which suggests that the technical scope of the applications is quite diverse within the Biotechnology & Pharmaceuticals sector.
LOCKARD, JON MCCLELLAND is the busiest examiner for this portfolio, with 1 busiest examiner pending action currently assigned. Since there are 3 pending office actions in total and 3 distinct examiners, each examiner is responsible for only 1 case. This lack of examiner concentration means that the company must navigate 3 separate prosecution paths without the benefit of a single primary examiner.
For practitioners, the involvement of 3 distinct art units and 3 distinct examiners implies that there is no central point of influence in the current portfolio. The strategy for the foundation must be highly adaptable to the various standards of the 3 distinct art units. Success will depend on managing the 3 pending office actions individually, as the 1 busiest examiner pending action under LOCKARD, JON MCCLELLAND represents only a portion of the total activity.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOCKARD, JON MCCLELLAND | 1 | 74.4% | +27.4% |
| MYERS, CARLA J | 1 | 49.5% | +46.0% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
| KIPOUROS, HOLLY MICHAELA | 1 | 69.8% | +21.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906165 | METHOD FOR PRODUCING BANKABLE AND SUBCULTURABLE MATURE MICROGLIA | SCHUBERG, LAURA J | 44d overdue |
| 18686643 | COMPOSITION FOR PREVENTING, TREATING OR AMELIORATING POOR OVARIAN RESPONSE SYNDROME COMPRISING RGMC | LOCKARD, JON MCCLELLAND | — |
| 17782541 | BIOMIMETIC NERVE CHIP FOR EVALUATING EFFICACY AND TOXICITY ON NERVE, AND USE THEREOF | KIPOUROS, HOLLY MICHAELA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906165 | METHOD FOR PRODUCING BANKABLE AND SUBCULTURABLE MATURE MICROGLIA | SCHUBERG, LAURA J | 44d overdue |
| 17905132 | OVARIAN RESERVE BIOMARKER AND USE THEREOF | MYERS, CARLA J | 2d overdue |
| 18686643 | COMPOSITION FOR PREVENTING, TREATING OR AMELIORATING POOR OVARIAN RESPONSE SYNDROME COMPRISING RGMC | LOCKARD, JON MCCLELLAND | — |
| 17782541 | BIOMIMETIC NERVE CHIP FOR EVALUATING EFFICACY AND TOXICITY ON NERVE, AND USE THEREOF | KIPOUROS, HOLLY MICHAELA | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1682 | 1 |
| 1631 | 1 |
| 1799 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686643 | COMPOSITION FOR PREVENTING, TREATING OR AMELIORATING POOR OVARIAN RESPONSE SYNDROME COMPRISING RGMC | LOCKARD, JON MCCLELLAND | 1647 | §101§102§112 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 17905132 | OVARIAN RESERVE BIOMARKER AND USE THEREOF | MYERS, CARLA J | 1682 | §103 | Final Rejection | 2d overdue | Pending | Nov 30, 2022 |
| 17906165 | METHOD FOR PRODUCING BANKABLE AND SUBCULTURABLE MATURE MICROGLIA | SCHUBERG, LAURA J | 1631 | §103 | Non-Final OA | 44d overdue | Pending | Sep 12, 2022 |
| 17782541 | BIOMIMETIC NERVE CHIP FOR EVALUATING EFFICACY AND TOXICITY ON NERVE, AND USE THEREOF | KIPOUROS, HOLLY MICHAELA | 1799 | §103§112 | Final Rejection | — | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCha University Industry-Academic Cooperation Foundation has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Jon Mcclelland Lockard has the most, with 1 of Cha University Industry-Academic Cooperation Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
